Is Standalone Salpingectomy Worth It for Ovarian Cancer?
Evaluating Standalone Salpingectomy for Ovarian Cancer
Ovarian cancer remains one of the most lethal gynecologic malignancies worldwide. Most high-grade serous ovarian carcinomas actually originate in the fimbriated ends of the fallopian tubes. Consequently, clinicians routinely endorse opportunistic salpingectomy during planned pelvic procedures. However, many individuals with elevated risk lack indications for concurrent pelvic surgery. A recent health economics study evaluated whether standalone salpingectomy offers a cost-effective alternative for primary prevention.
Modeling Risk-Stratified Standalone Salpingectomy
The researchers constructed a state-transition Markov model across five age cohorts: 35, 40, 45, 50, and 60 years. In addition, the investigators compared standalone salpingectomy against no surgical intervention. They evaluated populations at average risk alongside cohorts with elevated relative risks. Furthermore, they adopted a societal economic perspective with a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY).
For the general population, standalone salpingectomy was not cost-effective. Specifically, the incremental cost-effectiveness ratios ranged from $239,736 per QALY at age 50 to $288,870 per QALY at age 35. Standalone surgery added approximately $6,100 to $6,225 in lifetime costs per person. Moreover, it provided modest health gains of only 0.02 to 0.03 QALYs in average-risk individuals. Therefore, routine surgical intervention remains unfeasible for the general populace.
Clinical Implications for Moderate-Risk Patients
The economic calculus changed dramatically for patients facing moderate risk. For instance, at a relative risk of 1.5, the incremental ratios dropped to between $142,516 and $172,112 per QALY. Consequently, standalone salpingectomy became cost-effective for women aged 45 and 50. Additionally, when relative risk reached 2.0, the procedure proved cost-effective across all age groups. In fact, incremental ratios fell to between $97,336 and $118,544 per QALY.
Overall, the threshold relative risk required for cost-effectiveness ranged from 1.44 to 1.67 across cohorts. Thus, gynecologists should actively identify patients with moderately elevated baseline risk. For example, individuals with familial clusters or moderate-penetrance genetic variants benefit substantially. As a result, surgeons can confidently discuss prophylactic salpingectomy to preserve ovarian endocrine function while lowering cancer risk.
Frequently Asked Questions
Q1: What is the difference between opportunistic and standalone salpingectomy?
Opportunistic salpingectomy occurs during another scheduled abdominal or pelvic operation. In contrast, standalone salpingectomy is an independent surgical procedure performed solely for ovarian cancer prevention.
Q2: Is standalone salpingectomy cost-effective for average-risk individuals?
No, health economic models show that standalone salpingectomy is not cost-effective for the general population. Specifically, incremental cost-effectiveness ratios exceed standard willingness-to-pay thresholds due to high procedural costs and modest population-level absolute risk reduction.
Q3: At what risk level does standalone salpingectomy become cost-effective?
Standalone salpingectomy becomes cost-effective when a patient's relative risk for ovarian cancer reaches 1.44 to 1.67. Furthermore, it is cost-effective across all adult age groups when relative risk reaches 2.0.
References
- Lazovic S et al. Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis. Am J Obstet Gynecol. 2026 Sep 18. doi: undefined. PMID: 42759752.
- Dilley J, Havrilesky LJ, Moss HA. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol. 2017;146(2):373-379.
- Steenbeek MP, Harmsen MJ, Hermens RPMG, et al. Opportunistic salpingectomy for the prevention of ovarian cancer: A systematic review. Int J Gynecol Cancer. 2023;33(11):1733-1740.
